Professional research reports powered by Noah AI — grounded in 100M+ sources including PubMed, clinical trials, guidelines, and patents.
A concise review of how AAV gene therapy matured across engineering, manufacturing, safety, and clinical translation in ocular and neuromuscular disease.
EGFR-targeted therapy in NSCLC evolved from genotype-guided TKIs to osimertinib-centered care, with resistance heterogeneity driving bispecific, ADC, and C797S-era strategies.
Across regions, ILD outcomes remain constrained by delayed diagnosis, limited multidisciplinary access, treatment barriers, and fragmented longitudinal care.
siRNA lipid therapies, led by inclisiran, illustrate how LDL-C surrogate success shapes R&D, access, and long-term outcomes uncertainty.
Clinical oncology data increasingly shape how investors understand biotech value, influencing financing, IPO positioning, and broader views on strategic potential.
The review clarifies the strategic logic behind CAR-T transactions by highlighting the clinical, regulatory, manufacturing, and platform factors prioritized by buyers.
Despite CAR-T success in hematologic cancers, its application in NSCLC remains limited by antigen heterogeneity, immunosuppressive microenvironments, trafficking barriers, and safety concerns.
MASH is entering a defining phase, with near-term progress shaped by confirmatory evidence, reimbursement decisions, diagnostic pathway standardization, and supportive policy shifts.
VEGF-plus-immunotherapy benefits selected NSCLC populations, but efficacy depends on regimen, biology, and tolerability, rather than representing a universally effective class.
NSCLC immunotherapy is increasingly differentiated by setting, biomarkers, regional competition, and new agents aiming to improve durability and overcome resistance.
The oral GLP-1 landscape is beginning to take clearer shape, with future market direction likely to reflect a balance of regulatory progress, tolerability, and practical clinical value.
Radioligand therapy has become a commercially validated oncology modality, with competitive advantage increasingly driven by isotope supply, manufacturing integration, and theranostic execution.
This review summarizes recent advances in rheumatoid arthritis biology and therapy, highlighting precision medicine opportunities, safety concerns, and persistent unmet clinical needs.
This article reviews PCSK9’s pleiotropic biology beyond LDLR, evaluating inflammation, Lp(a), apoB metabolism, and emerging therapies with translational evidence.
A recent perspective debates whether additional TKIs are still needed in CML, arguing that despite major progress, ongoing issues with resistance, intolerance, and optimal sequencing leave room for further innovation.
Mechanistically diverse MASLD/MASH therapies show strong histologic signals but uncertain clinical translation, limited by fibrosis biology, tolerability, and biomarker gaps
An integrated pre-LOE playbook aligning clinical, regulatory, commercial, and financial levers can mitigate erosion and preserve oncology franchise value amid biosimilar entry.
Recent Chinese and US hypertension guidelines converge on intensive treatment targets and core first-line therapies, yet diverge in diagnostic thresholds and pharmacotherapy initiation for low-risk stage 1 hypertension.
Feb 2025–Feb 2026 oncology deals favored fewer, larger transactions: milestone-heavy early licenses, mostly upfront M&A, modality innovation, rising China out-licensing.
GalNAc-targeted siRNA/ASO therapies enable durable hepatocyte gene silencing of metabolic regulators, improving lipids/NASH targets with infrequent dosing and ongoing outcomes validation.